Here’s What Analysts Are Saying About Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best medical research stocks to buy according to hedge funds. Bernstein reiterated its Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) on February 10 and set a price target of $58.00. Bristol-Myers Squibb Company (NYSE:BMY) also received a rating update from Morgan Stanley on February 6, which lifted the price target on the stock to $40 from $37 while keeping an Underweight rating on the shares. The firm told investors in a research note that while the 2026 revenue and EPS guidance exceeded consensus, it was driven by a higher-than-expected Eliquis guide.

In addition to Morgan Stanley, BofA also raised the price target on Bristol-Myers Squibb Company (NYSE:BMY) to $68 from $64 on February 6 and maintained a Buy rating on the shares. The firm lifted its near-term forecasts after the company delivered fiscal Q4 and FY26 guidance beats, telling investors that  Bristol-Myers Squibb Company (NYSE:BMY) “is a pipeline story”.

The same day, Guggenheim also raised the price target on the stock to $72 from $62, maintaining a Buy rating on the shares and raising its view of the odds of success to 90% for iber/mezi from the previous 33%. The firm also increased its view of the odds of success to 90% from 75% prior for milvexian in SSP, stating that it is continuing to recommend that investors buy shares ahead of the company’s “series of high-profile, potentially high-reward” Phase 3 catalysts.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.